✦ LIBER ✦

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

✍ Scribed by Thomas E. Stinchcombe; Mark A. Socinski; Christine M. Walko; Bert H. O’Neil; Frances A. Collichio; Anastasia Ivanova; Hua Mu; Michael J. Hawkins; Richard M. Goldberg; Celeste Lindley; E. Claire Dees

Publisher: Springer
Year: 2007
Tongue: English
Weight: 388 KB
Volume: 60
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-007-0423-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I and pharmacokinetic study of nab

Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer

✍ Masashi Ando; Kan Yonemori; Noriyuki Katsumata; Chikako Shimizu; Taizo Hirata; H 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 361 KB

A phase II trial of nab-paclitaxel (ABI-

A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : A North Central Cancer Treatment Group Study, N057E1

✍ Lisa A. Kottschade; Vera J. Suman; Thomas Amatruda III; Robert R. McWilliams; Ba 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 2 views

A phase I, pharmacokinetic and pharmacod

A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-α2b in patients with solid tumors

✍ Bryan Schneider; Anna Fukunaga; Daryl Murry; Christy Yoder; Karen Fife; Anne Fos 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 334 KB

A phase I trial of ifosfamide and paclit

A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors

✍ Craig A. Bunnell; Lynn Thompson; Lori Buswell; Ross Berkowitz; Michael Muto; Ell 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## Background: Ifosfamide and paclitaxel are antineoplastic agents with broad activity and with different mechanisms of action. a phase i trial was conducted to determine the maximum tolerated dose and associated toxicities of these agents when used in combination. ## Methods: Patients with refra

Phase I and pharmacokinetic study of lon

Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors

✍ Carlos Castaneda; Kellen L. Meadows; Roxanne Truax; Michael A. Morse; Scott H. K 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 358 KB